Drugs / SF0166
SF0166
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02914639 | Oct 2016 → Jun 2017 | age-related macular degeneration | OcuTerra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02914613 | Aug 2016 → May 2017 | diabetic macular edema | OcuTerra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05409235 | Jul 2022 → Dec 2023 | diabetic retinopathy | OcuTerra Therapeutics, Inc. | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SF0166 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02914613 ↗ |
| Known as | NESVATEGRAST ISOBUTANOLAMMONIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315046 ↗ |
| Known as | OTT166 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05409235 ↗ |
| Modality | Small molecule | — CHEMBL5315046 ↗ |
| Route | Other | “SF0166 low dose instilled in study eye BID for 28 days of treatment.” NCT02914613 ↗ |